DIRS.INFO The most relevant business & tech news

☆ Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members
▼ + stars: | 2023-11-13 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Monday emphasized his belief that GLP-1 drugs primarily used to treat diabetes and obesity and the companies that make them, like Eli Lilly and Novo Nordisk , will be very valuable. And for millions of people, it'll be cheaper for the insurance companies to shell out for the new weight-loss drugs than to let their morbidly obese members just get heart disease," he said. Cramer called these drugs "revolutionary," citing new data from Novo Nordisk suggesting its drug Wegovy cut the risk of serious cardiovascular complications in patients with obesity and heart disease by 20%. For example, type two diabetes can put patients at risk for other health issues, so insurance companies would want to pay for the drugs in order to prevent further complications, he said. Similarly, those with obesity and treatment-resistant high blood pressure are at higher risk for heart disease, making them primary candidates for the drugs.

Persons: CNBC's Jim Cramer, Eli Lilly, Cramer Organizations: Novo Nordisk

☆ An ‘Unsettling’ Drop in Life Expectancy for Men
▼ + stars: | 2023-11-13 | by ( Azeen Ghorayshi | More About Azeen Ghorayshi | ) www.nytimes.com time to read: +2 min

Background: The life expectancy gap has substantially widened — and shrunk — before. At the turn of the 20th century, women had a life expectancy just two years higher than men, Dr. Yan said. That year, the life expectancy for men was 76.3 years, while for women it was 78.1. Between 2019 and 2021, the life expectancy in the United States dropped from around 79 to 76 years. Unintentional injuries — mostly drug overdoses — contributed to more than 30 percent of the life expectancy gap between men and women.

Persons: Yan, Covid, —, ” Dr Locations: United States

Eight of the 11 major S&P 500 sectors were in the red, with rate-sensitive real estate stocks (.SPLRCR) down 1.2% and leading declines. This week's economic data as well as speeches from Fed officials will provide clues on the trajectory of interest rates amid growing expectations that the Fed is done hiking borrowing costs. The major U.S. stock indexes have rebounded strongly this month, fueled by a stronger-than-expected earnings season and on hopes that U.S. interest rates are near their peak. The benchmark S&P 500 (.SPX) closed at near eight-week highs on Friday, while the tech-heavy Nasdaq (.IXIC) hit a two-month peak. The S&P index recorded 11 new 52-week highs and one new low, while the Nasdaq recorded 19 new highs and 82 new lows.

Persons: Brendan McDermid, Peter Cardillo, Cardillo, Mike Johnson, Abbott, advancers, Sruthi Shankar, Amruta, Maju Samuel Organizations: New York Stock Exchange, REUTERS, Boeing, Dow, Nasdaq, Federal Reserve, Treasury, Microsoft, Apple, Spartan Capital Securities, . House, Republican, Dow Jones, Novo Nordisk's, Bloomberg News, Max, NYSE, Thomson Locations: New York City, U.S, China, Bengaluru

☆ Here's what Wall Street is saying about obesity drug Wegovy following Novo Nordisk's key study
▼ + stars: | 2023-11-13 | by ( Alex Harring | ) www.cnbc.com time to read: +6 min

Wegovy contains semaglutide, the same active ingredient in Novo's type 2 diabetes drug Ozempic. A rising tide for Eli Lilly? Though the study was specifically about Wegovy, Wall Street sees a positive readthrough for similar medications from other providers, particularly Eli Lilly 's Zepbound. Similarly, UBS analyst Trung Huynh called the weekend data a "best-case" scenario for Eli Lilly. And the positive outcomes for both in the Wegovy study can be viewed as encouraging for how Zepbound should perform, the analyst added.

Persons: Morgan Stanley, Mark Purcell, Richard Vosser, Peter Verdult, Eli Lilly, Eli Lilly's, Lilly, Andrew Baum, Trung Huynh, That's, it's, Zepbound, Huynh, Citi's Baum, James Shin isn't, Michael Bloom, Christina Cheddar Berk, Angelica Peebles Organizations: Novo Nordisk, American Heart Association, cardiologists, JPMorgan, Citi, ., UBS, North American, Tandem Diabetes Care, Deutsche Bank

☆ The Bodily Indignities of the Space Life
▼ + stars: | 2023-11-12 | by ( Kim Tingley | ) www.nytimes.com time to read: +5 min

But the space-based medical science needed to make that possible has been hindered by small sample sizes that aren’t representative of the general population. As less-rigorous medical screening allows more tourists to reach space, the chances increase significantly that someone will get hurt or have a health emergency there. And if we survived those perils, wouldn’t escalating pressure in our skulls kill us after a week or so? Initially, many space travelers puke, or at least feel motion-sick — space-adaptation syndrome, or S.A.S., is what such nausea, headache and vomiting are called outside our atmosphere. symptoms in the 1970s, when they heard Skylab astronauts talking about it with one another over a hot mic.

Persons: Donoviel, TRISH, ” Donoviel, Yuri Gagarin, humanity’s, hadn’t, Gagarin, ”, Jan Stepanek, “, acclimate Organizations: Apollo, Institute, Space Health, Baylor College of Medicine, NASA, Aerospace, American Board of Preventive, Mayo Clinic Locations: Scottsdale, Ariz

The popular weight-loss drug Wegovy reduced the risk of serious heart problems by 20% in a large, international study that experts say could change the way doctors treat certain heart patients. Wegovy is a high-dose version of the diabetes treatment Ozempic, which already has been shown to reduce the risk of serious heart problems in people who have diabetes. Study volunteers who took Wegovy lost about 9% of their weight while the placebo group lost less than 1%. About 17% in the Wegovy group and about 8% in the comparison group left the study, mostly because of nausea, vomiting, diarrhea and other stomach-related problems. In 2006, Medicare was allowed to cover weight-loss surgery to treat the complications of severe obesity, if not obesity itself, he noted.

Persons: Wegovy, pare, ”, Michael Lincoff, hasn’t, Dr, Francisco Lopez, Jimenez, Lopez, Martha Gulati, Gulati, Eli Lilly's Zepbound, Mark McClellan Organizations: Cleveland Clinic, Mayo Clinic, New England, of Medicine, Novo Nordisk, U.S . Food, Drug Administration, Sinai Medical Center, Medicare, Centers, Services, FDA, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, Philadelphia, Novo, Los Angeles

☆ Novo Nordisk says Wegovy heart benefits due to more than weight loss
▼ + stars: | 2023-11-11 | by ( Patrick Wingrove | ) www.reuters.com time to read: +4 min

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing RightsPHILADELPHIA, Nov 11 (Reuters) - Novo Nordisk (NOVOb.CO) on Saturday said the heart protective benefits of its wildly popular Wegovy obesity treatment are due to more than weight loss alone, according to new data presented at a major medical meeting on Saturday. Given that patients had not started losing weight when the cardiovascular benefits first appeared suggests the heart protection was not purely the result of weight loss, Novo said. Though the trial was not conducted to test weight loss, participants lost an average of nearly 10% of their total body weight. Novo said patients in the heart study were not required to track diet and exercise as they are in obesity trials.

Persons: Victoria Klesty, Wegovy, Novo, Martin Lange, Lange, Eli Lilly's, Patrick Wingrove, Bill Berkrot Organizations: REUTERS, Rights, Novo Nordisk, American Heart Association, New England, of Medicine, Novo Nordisk's, U.S . Food, Drug Administration, Thomson Locations: Oslo, Norway, Victoria, Philadelphia, U.S, EU

☆ Cutting 1 teaspoon of salt works as well as blood pressure meds, study finds
▼ + stars: | 2023-11-11 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

CNN —Cutting 1 teaspoon of salt from your diet each day can lower your top blood pressure reading just as much as a typical hypertension medication, even if you don’t have high blood pressure, a new study found. Wirestock/iStockphoto/Getty ImagesNearly half of all Americans live with high blood pressure, according to the American Heart Association. Compared to the high-sodium diet, blood pressure on the extremely low-salt diet dropped 8 millimeters of mercury. “Compared to their normal diet, people reduced their blood pressure by about 6 millimeters of mercury, about the same effect you’d see for a first-line blood pressure medication,” Allen said. “Taste bud adjustment takes a little bit longer, but the blood pressure improvements are pretty quick,” she added.

Persons: ”, Norrina Allen, ” Allen, Andrew Freeman, Freeman, bouillon, “, Allen, ” Freeman, Dietitians Organizations: CNN, American Heart Association, Northwestern University’s Feinberg School of Medicine, World Health Organization, Jewish Health, National Library of Medicine Locations: Denver

☆ Trial confirms heart benefits of Wegovy, but is weight loss responsible – or something else?
▼ + stars: | 2023-11-11 | by ( Meg Tirrell | ) edition.cnn.com time to read: +9 min

To cardiologist Dr. Steven Nissen of the Cleveland Clinic, who wasn’t involved in the trial but is leading a similar one of tirzepatide, those effects are all evidence of the benefits of weight loss. Tirzepatide has shown greater levels of weight loss than semaglutide in clinical trials, leading many, including Nissen, to hope it will show even stronger cardiovascular benefits. Importantly, participants didn’t have a history of diabetes; a previous trial had shown that treating people with diabetes with a GLP-1 drug, Ozempic, reduced their cardiovascular risk. The Wegovy trial showed that 569 of 8,803 people taking the drug had a heart attack or stroke or died from heart-related causes, or 6.5%. The amount of weight loss seen in the trial, 9.4%, was less than in other studies of Wegovy, which showed average weight loss closer to 15%.

Persons: Ania Jastreboff, Wegovy, Dr, Amit Khera, National Institutes of Health’s Dr, Tiffany M, Powell, Wiley, Eli Lilly, Steven Nissen, wasn’t, ” Nissen, “, Tirzepatide, Nissen, Michael Lincoff, Lincoff, ”, Jastreboff, Sanjay Gupta, hadn’t, “ semaglutide Organizations: CNN, Nordisk’s Wegovy, American Heart Association, Yale Obesity Research Center, University of Texas Southwestern Medical Center Dallas, National Institutes of Health’s, New England, of Medicine, US Food and Drug, Cleveland Clinic, Novo Nordisk, Cleveland, CNN Health Locations: Philadelphia, Powell

☆ Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events
▼ + stars: | 2023-11-11 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Novo Nordisk's Wegovy cut the risk of serious cardiovascular complications in people with obesity and heart disease in a closely watched trial, demonstrating a particularly large effect on heart attacks, a promising new frontier for the drug. The roughly 17,500-person Select study tested Wegovy in people with obesity and heart disease but who did not have diabetes. The new data could also help the Danish pharmaceutical company maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was approved in the U.S. earlier this week. Zepbound has been shown to help people lose more weight, but it hasn't yet demonstrated an effect on cardiovascular outcomes.

Persons: Robert Kushner, Eli Lilly, Zepbound, Howard Weintraub Organizations: Wegovy, American Heart Association Scientific Sessions, New England, of Medicine, Novo Nordisk, Northwestern University Feinberg School of Medicine, Center for, NYU Langone Locations: Danish, U.S

☆ Wegovy Is Shown to Reduce Risk of Heart Attacks and Strokes in Some Patients
▼ + stars: | 2023-11-11 | by ( Dani Blum | More About Dani Blum | ) www.nytimes.com time to read: +1 min

A pivotal new study suggests that the weight loss drug Wegovy cut the risk of heart attack, stroke or death from cardiovascular issues by 20 percent among overweight or obese people with heart disease — a striking benefit that could change the standard of care for these patients. “We’ve just identified a new best practice,” said Dr. Clyde Yancy, chief of the division of cardiology at Northwestern Medicine, who was not involved with the study. Drug companies see potential for the medicines that extends far beyond obesity. Outside of statins, she said, no medication has so dramatically reduced cardiovascular risk among people with heart disease. “The uptake of this drug is going to be skyrocketing in the next couple of years,” she said.

Persons: “ We’ve, ”, Clyde Yancy, Yuan Lu Organizations: Northwestern Medicine, American Heart Association, Yale School of Medicine Locations: Philadelphia, statins

The company's research and development (R&D) engine is intact and therefore it is unlikely to do transformative deals soon, Jorgensen said. It was the latest in a series of similarly-sized deals the company has done this year. Last week, when reporting quarterly earnings, it forecast another year of double-digit sales growth for its two most popular drugs: weight-loss drug Wegovy and diabetes Ozempic. To keep up with demand, Novo is racing to increase production of those drugs, which contain the same active pharmaceutical ingredient, semaglutide, and are delivered in self-injection pens. A healthcare banker, speaking on condition of anonymity, told Reuters after the interview there were many companies in the cardiometabolic space with early-stage drugs that Novo Nordisk may be able to buy.

Persons: Lars Fruergaard Jorgensen, Wegovy, Jorgensen, Novo, Novo's, Jacob Gronholt, Maggie Fick, Terje Solsvik, Emelia, Barbara Lewis Organizations: Novo, Novo Nordisk, Reuters, KBP Biosciences, Nordisk, Pedersen, Thomson Locations: Novo, COPENHAGEN, Singapore, Copenhagen, London

CNN —Media personality and sex expert Dr. Ruth Westheimer is now New York state’s honorary ambassador to loneliness, a role that’s the first of its kind in the nation. US Surgeon General Vivek Murthy has described the prevalence of loneliness and isolation as a national epidemic among all ages. Dr. Ruth Westheimer arrives at the Governors Awards at the Dolby Ballroom in Los Angeles on October 27, 2019. A sense of being alone defines loneliness, while social isolation is an objective lack of social connections. Social isolation has also been linked to cognitive decline, anxiety and weakened immunity.

Persons: Ruth Westheimer, Kathy Hochul, Westheimer, Vivek Murthy, Jordan Strauss, ” Westheimer, “, ” Hochul, ”, Hochul, ” Greg Olsen, Olsen, Hochul’s, ” Olsen Organizations: CNN — Media, New York, New York Gov, US Centers for Disease Control, Dolby, Aging, New York State Office, National Academies of Sciences, Engineering, Medicine Locations: New, Los Angeles, As New York, Germany, New York, —

☆ Lilly trades at a premium to Ozempic-maker Novo as obesity drugs boom. Here's why, analyst says
▼ + stars: | 2023-11-10 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +6 min

Does Eli Lilly deserve to trade at a premium to Novo Nordisk shares? LLY YTD mountain Eli Lilly shares since the start of the year. According to Shin, Lilly deserves a premium to Novo Nordisk because its portfolio is more diverse and it has less exposure to insulin. NVO YTD mountain Novo Nordisk shares year to date In the coming weeks, Lilly will start rolling out Zepbound to patients. Novo Nordisk is scheduled to release the full results of its Select cardiovascular trial at the American Heart Association conference.

Persons: Eli Lilly, James Shin, Shin, Lilly, We're, Lilly's, Zepbound, Wegovy, Chris Schott, Karsten Munk Knudsen, Novo, Schott, AstraZeneca, Eccogene, David Ricks, — CNBC's Michael Bloom Organizations: Novo Nordisk, Deutsche Bank, Biotech, Pharma, Centers for Disease Control, Novo, CNBC, American Heart Association Locations: U.S, GLP, Novo, Denmarkt

☆ Best ways to counter the harmful effects of sitting, according to research
▼ + stars: | 2023-11-10 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

CNN —Sitting too much may send you to an early death, likely from chronic diseases such as obesity, type 2 diabetes, cardiovascular disease and more, according to research. “The question is, if you have a restorative or recharging sleep, is that better than sitting on the couch eating and watching TV? While the study found swapping sitting for sleep improved health, benefits were not equal, the authors said. More vigorous exercise is best, but standing, walking and even sleeping is better than just sitting, experts say. “Since most songs average at least 3 minutes, you can dance off the negative impact of too much sitting.

Persons: ”, Andrew Freeman, ” Freeman, Mark Hamer, ” Hamer, Emmanuel Stamatakis, Kobus, “, Jo Blodgett, James Leiper, ” Leiper, that’s, Dana Santas, ” Santas, Santas Organizations: CNN’s, CNN, BMI, Jewish Health, Institute of Sport, Health, University College London, University of Sydney, British Heart Foundation Locations: waistlines, Denver, Australia, Belgium, Denmark, Finland, Norway, Spain, Netherlands, United Kingdom, United States

As the company's fortunes soar on demand for its popular weight-loss medicine Wegovy, Jorgensen said Novo sought to acquire companies working on medicines in the areas where it is already focused. The company's research and development (R&D) engine is intact and therefore it is unlikely to do transformative deals soon, Jorgensen said. It was the latest in a series of similarly-sized deals the company has done this year. Last week, when reporting quarterly earnings, it forecast another year of double-digit sales growth for its two most popular drugs: weight-loss drug Wegovy and diabetes Ozempic. To keep up with demand, Novo is racing to increase production of those drugs, which contain the same active pharmaceutical ingredient, semaglutide, and are delivered in self-injection pens.

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. The U.S. Food and Drug Administration on Wednesday said Eli Lilly (LLY.N) could begin selling its drug tirzepatide for weight loss, making it the second obesity drug in a class known as GLP-1s. Studies of Novo's Wegovy showed that it led to 15% weight loss over 68 weeks, while Lilly's drug, which also targets a second hormone called GIP, demonstrated weight loss of more than 22% over 72 weeks. Drugstore chain Walgreens is seeing "enormous demand" for GLP-1s, said John Driscoll, president, U.S. healthcare at Walgreens Boots Alliance (WBA.O). Much has been made of the impact the new weight loss drugs might have on consumer habits such as snack food purchases, but Driscoll said Walgreens has not seen that yet.

Persons: Victoria Klesty, Eli Lilly, Novo, Novo's Wegovy, Lawrence Tabak, John Driscoll, Tabak, Driscoll, Walgreens, Julie Steenhuuysen, Caroline Stauffer, Deena Beasley, Jamie Freed Organizations: REUTERS, Rights, Reuters, Total Health, U.S . Food, Drug Administration, U.S . National Institutes of Health, Walgreens, Walgreens Boots Alliance, Thomson Locations: Oslo, Norway, August31, Victoria, Chicago, U.S, satiety

☆ Social isolation linked to early death risk, study finds
▼ + stars: | 2023-11-09 | by ( Kristen Rogers | ) edition.cnn.com time to read: +6 min

Those who don’t socialize with friends or family may see their risk of dying early increase by 39%. Many previous studies have linked loneliness or social isolation with a higher risk of premature death and other health outcomes. But few, if any, have looked into how these associations depend on the combined impact of different types of social interaction, according to a new study published Thursday in the journal BMC Medicine. Participants’ social isolation was gauged by how often they were visited by friends or family, how often they engaged in weekly group activities, and whether they lived alone. It’s also possible that any of these factors could lead to loneliness or social isolation rather than result from them, according to the study.

Persons: “, ”, Hamish Foster, weren’t, Anthony Ong, —, It’s, Foster, Jason Gill, Olivia Remes, wasn’t, Gill Organizations: CNN, BMC Medicine, School of Health, University of Glasgow, Cornell University, University of Cambridge, Social, Networks Locations: Scotland, United Kingdom, New York, England

☆ Eli Lilly receives approval for its weight-loss drug. But here's what could boost the stock next
▼ + stars: | 2023-11-08 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +4 min

Shares of Eli Lilly (LLY) jumped Wednesday after the U.S. government gave the green light for the company's blockbuster GLP-1 drug to be used as an obesity treatment. In a widely expected move, the U.S. Food and Drug Administration on Wednesday approved Eli Lilly's GLP-1 drug for weight loss. Eli Lilly said it will market the drug as an obesity treatment under the name Zepbound. Shares of Eli Lilly — which have climbed more than 67% year-to-date — soared nearly 2% Wednesday afternoon, to $611.36 apiece. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, LLY, Eli Lilly's GLP, Eli Lilly —, Eli Lilly's, Jim Cramer, Jim, Jim Cramer's, Cristina Arias Organizations: U.S, U.S . Food, Drug Administration, American Heart Association, Novo Nordisk, Novo, GLP, Nordisk's GLP, FDA, Nordisk, CNBC, Company, Pharmaceutical Locations: U.S, Danish, Alcobendas, Madrid, Spain

☆ FDA approves Eli Lilly's tirzepatide for weight loss, paving way for wider use of blockbuster drug
▼ + stars: | 2023-11-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

George Frey | ReutersThe Food and Drug Administration on Wednesday approved Eli Lilly 's blockbuster drug tirzepatide for weight loss, paving the way for even wider use of the treatment in the U.S. The FDA said the approval was based on two of Eli Lilly's late-stage trials on tirzepatide, which evaluated its effects on weight loss after 72 weeks. Higher doses of the drug were associated with even more weight loss, with a 15-milligram dose leading to 22.5% weight loss on average. The bigger issue is that many insurance companies are dropping weight loss drugs from their plans. Preliminary data is already available: A recent late-stage trial found that Novo Nordisk's weight loss drug Wegovy reduced the risk of cardiovascular events such as heart attack and stroke by 20%.

Persons: George Frey, Eli Lilly, John Sharretts, Eli Lilly's, Wegovy, Lilly, Mike Mason, Eli Lilly Diabetes Organizations: Novo Nordisk, Pharmacy, Reuters, Food, Drug Administration, U.S, FDA's Center, Drug, FDA, Obesity Locations: Provo , Utah, U.S, United States

☆ Marijuana use raises risk of heart attack, heart failure and stroke, studies say
▼ + stars: | 2023-11-06 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +6 min

CNN —Older adults who don’t smoke tobacco but do use marijuana were at higher risk of both heart attack and stroke when hospitalized, while people who use marijuana daily were 34% more likely to develop heart failure, according to two new non-published studies presented Monday at the American Heart Association Scientific Sessions in Philadelphia. “You need to treat this just like you would any other risk factor (for heart disease and stroke), and honestly understand the risks that you were taking,” he said. Heart failure doesn’t mean the heart has stopped working, but that the heart isn’t pumping oxygenated blood as well as it should, according to the AHA. At the end of the study, researchers found people who reported daily marijuana use had a 34% increased risk of developing heart failure, compared to those who reported never using marijuana. Also called atherosclerosis, CAD is the most common type of heart disease, according to the US Centers for Disease Control and Prevention.

Persons: ” Robert Page II, ”, Westend61, Avilash, ” Page, it’s, Yakubu Bene, Alhasan Organizations: CNN, American Heart Association Scientific Sessions, Heart, Cannabis, Cardiovascular Health, University of Colorado Skaggs School of Pharmacy, Pharmaceutical Sciences, National Institute on Drug Abuse, Nazareth Hospital, AHA, US Centers for Disease Control, Health Locations: Philadelphia, Aurora , Colorado, Baltimore

☆ These are Mizuho's top stock picks heading into November
▼ + stars: | 2023-11-05 | by ( Alex Harring | ) www.cnbc.com time to read: +3 min

Mizuho's equity research team compiled its top buy-rated picks for the new month. The average price target for the stock, which is already up about 14% this year, implies an upside of about 15%. But the average analyst is bullish with a buy rating and price target implying an upside of almost 21%, per LSEG. The average Wall Street analyst rates EyePoint a buy, and the consensus price target implies the stock could skyrocket nearly 290%, per LSEG. The average analyst has a buy rating and price target reflecting 13.5% upside ahead, per LSEG.

Persons: Nitin Kumar, Mara Goldstein, Graig Suvannavejh, Siti Panigrahi, INTU, Panigrahi, — CNBC's Michael Bloom Organizations: Mizuho, Dow Jones, Nasdaq, Coterra Energy, Merck, Co, EyePoint Pharmaceuticals, Intuit, Small Locations: Keytruda

☆ Too Much Salt Could Raise Your Odds for Diabetes
▼ + stars: | 2023-11-03 | by ( Nov. | At A.M. | ) www.usnews.com time to read: +2 min

By Cara Murez HealthDay Reporter(HealthDay)FRIDAY, Nov. 3, 2023 (HealthDay News) -- Put down the saltshaker — especially if you’re at risk of type 2 diabetes. While the condition brings to mind the need to avoid sugar, a new study links it to frequent salt consumption. He is chair and professor at the Tulane University School of Public Health and Tropical Medicine in New Orleans. Over almost 12 years on average, the research team saw more than 13,000 cases of type 2 diabetes develop. Compared to those who “never” or “rarely” used salt, participants who “sometimes,” “usually” or “always” added salt had a respective 13%, 20% and 39% higher risk of developing type 2 diabetes, according to the study.

Persons: Cara Murez HealthDay, ”, . Lu Qi, “ It’s, ” Qi, “, it’s, Qi Organizations: Tulane University School of Public Health, Tropical Medicine, Mayo Clinic, U.S . Centers for Disease Control, Tulane University Locations: New Orleans, Mayo

☆ Sweet spot for HRT may reduce dementia risk by nearly a third, study says
▼ + stars: | 2023-11-02 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +8 min

Just how harmful or helpful hormone replacement therapy may be also depends on the type of hormones that are prescribed, especially at older ages. Estrogen-only hormone therapy can be prescribed if the uterus has been removed via hysterectomy. Scientists are developing a new generation of hormone replacement called selective estrogen receptor modulator, or SERM. Scientists are working on new forms of hormone replacement therapy that go directly to the brain, thus making them safer for menopausal women. In addition, some women are not candidates for hormone replacement therapy, perhaps due to family history, heart conditions or clotting disorders.

Persons: hasn’t, “, ”, Lisa Mosconi, Mosconi, Richard Isaacson, ” Isaacson, gynecologists, midlife, ” Mosconi Organizations: CNN, Weill Cornell Medicine, “ Locations: New York City, midlife, Florida

☆ Weight-loss drug Wegovy could get expanded FDA approval within six months, Novo Nordisk says
▼ + stars: | 2023-11-02 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +2 min

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. Michael Siluk | UCG | Getty ImagesNovo Nordisk said Thursday that its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months. "I would say from today, [the outcome will be] less than six months," Knudsen told CNBC's Julianna Tatelbaum on "Street Signs." watch nowEarlier Thursday, Novo Nordisk in its third-quarter earnings announced plans to get expanded approval from the FDA, but shared no timeline. "The SELECT study is, in an obese population with established cardiovascular disease, does Wegovy reduce cardiovascular risk?

Persons: Michael Siluk, Karsten Munk Knudsen, Knudsen, CNBC's Julianna Tatelbaum, " Knudsen, Novo Organizations: UCG, Getty, Novo Nordisk, U.S . Food, Drug Administration, CNBC, FDA, Novo Nordisk's Locations: U.S, Danish

Search resuls for: "Cardiovascular"

25 mentions found